Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented: "We are delighted to extend the availability of our groundbreaking Nu.Q® technology ...